AnaptysBio (NASDAQ:ANAB) Downgraded to Neutral Rating by BTIG Research

AnaptysBio (NASDAQ:ANAB) was downgraded by stock analysts at BTIG Research from a “buy” rating to a “neutral” rating in a research note issued on Monday, Marketbeat reports.

A number of other analysts have also recently commented on ANAB. UBS Group lifted their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Guggenheim lifted their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a research report on Thursday, August 15th. Wedbush restated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a research report on Thursday, November 14th. Finally, JPMorgan Chase & Co. cut their price target on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and an average price target of $54.64.

AnaptysBio Trading Down 0.6 %

Shares of ANAB opened at $24.96 on Monday. The company has a 50-day moving average of $28.13 and a two-hundred day moving average of $29.74. The stock has a market cap of $759.53 million, a P/E ratio of -4.11 and a beta of -0.24. AnaptysBio has a 12-month low of $13.96 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The firm had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, analysts forecast that AnaptysBio will post -6.02 EPS for the current fiscal year.

Insider Activity

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now owns 15,398 shares in the company, valued at approximately $595,440.66. This trade represents a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This trade represents a 72.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock valued at $892,936 in the last ninety days. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. purchased a new stake in AnaptysBio during the third quarter worth approximately $49,000. nVerses Capital LLC lifted its holdings in shares of AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares in the last quarter. Headlands Technologies LLC boosted its position in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares in the last quarter. Finally, Point72 DIFC Ltd raised its position in AnaptysBio by 680.5% in the third quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after purchasing an additional 5,342 shares during the period.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.